BHCM
FLGT icon

Brevan Howard Capital Management’s Fulgent Genetics FLGT Stock Holding History

Brevan Howard Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,541
Closed -$509K – 1961
2025
Q3 		$509K Buy
+22,541
New +$464K ﹤0.01% 1285
2025
Q2 		– Sell
-44,526
Closed -$752K – 1897
2025
Q1 		$752K Buy
+44,526
New +$758K 0.01% 597

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's FLGT Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Fulgent Genetics (FLGT) in Q4 2025, closing a stake of 22,541 shares — an estimated $509K sold.

Brevan Howard Capital Management first reported a position in FLGT in Q1 2025 and held it in 2 quarters. The position peaked at $752K in Q1 2025. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Fulgent Genetics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 22,541 Fulgent Genetics shares in Q4 2025, an estimated $509K.
  • Brevan Howard Capital Management first reported a position in Fulgent Genetics in Q1 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Fulgent Genetics position peaked at $752K in Q1 2025.
  • 179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.